The Advisory Board Co. (NASDAQ:ABCO) insider Hoose Mary Van sold 2,000 shares of the stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $34.26, for a total transaction of $68,520.00. Following the transaction, the insider now directly owns 37,386 shares of the company’s stock, valued at approximately $1,280,844.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

The Advisory Board Co. (NASDAQ:ABCO) opened at 32.85 on Tuesday. The stock has a 50 day moving average of $40.65 and a 200-day moving average of $38.42. The firm’s market capitalization is $1.32 billion. The Advisory Board Co. has a one year low of $18.87 and a one year high of $54.83.

The Advisory Board (NASDAQ:ABCO) last released its quarterly earnings results on Tuesday, November 1st. The company reported $0.28 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.40 by $0.12. The company earned $200.50 million during the quarter, compared to analysts’ expectations of $203.35 million. The Advisory Board had a positive return on equity of 11.28% and a negative net margin of 5.77%. The firm’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.33 EPS. On average, equities analysts predict that The Advisory Board Co. will post $1.82 EPS for the current year.

Insider Buying and Selling by Quarter for The Advisory Board (NASDAQ:ABCO)

Several research firms have recently commented on ABCO. Barclays PLC raised their price objective on shares of The Advisory Board from $44.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, September 30th. Canaccord Genuity set a $50.00 price objective on shares of The Advisory Board and gave the company a “buy” rating in a research note on Wednesday, September 28th. Zacks Investment Research lowered shares of The Advisory Board from a “hold” rating to a “sell” rating in a research note on Monday, October 17th. William Blair reissued an “outperform” rating on shares of The Advisory Board in a research note on Tuesday, September 27th. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $50.00 price objective on shares of The Advisory Board in a research note on Friday, September 16th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $43.25.

Institutional investors have recently added to or reduced their stakes in the company. TPG Group Holdings SBS Advisors Inc. boosted its position in The Advisory Board by 298.4% in the second quarter. TPG Group Holdings SBS Advisors Inc. now owns 2,144,589 shares of the company’s stock worth $75,897,000 after buying an additional 1,606,256 shares in the last quarter. Janus Capital Management LLC boosted its position in The Advisory Board by 146.3% in the second quarter. Janus Capital Management LLC now owns 1,744,564 shares of the company’s stock worth $61,739,000 after buying an additional 1,036,216 shares in the last quarter. Confluence Investment Management LLC boosted its position in The Advisory Board by 1,192.7% in the second quarter. Confluence Investment Management LLC now owns 614,292 shares of the company’s stock worth $21,740,000 after buying an additional 566,772 shares in the last quarter. Bernzott Capital Advisors bought a new position in The Advisory Board during the second quarter worth $18,812,000. Finally, FMR LLC boosted its position in The Advisory Board by 366.9% in the second quarter. FMR LLC now owns 622,874 shares of the company’s stock worth $22,044,000 after buying an additional 489,478 shares in the last quarter.

About The Advisory Board

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.

5 Day Chart for NASDAQ:ABCO

Receive News & Stock Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related stocks with our FREE daily email newsletter.